SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Consensus Price Target of $12.00

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $12.00.

Several brokerages have recently weighed in on SABS. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Weiss Ratings raised shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Barclays began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 target price for the company. Finally, Chardan Capital boosted their price target on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th.

SAB Biotherapeutics Price Performance

SABS stock opened at $2.98 on Wednesday. The stock has a 50-day moving average price of $3.59 and a two-hundred day moving average price of $3.69. SAB Biotherapeutics has a 1 year low of $1.97 and a 1 year high of $5.15. The stock has a market cap of $271.15 million, a PE ratio of -2.29 and a beta of 0.58. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). Equities analysts forecast that SAB Biotherapeutics will post -1.17 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SABS. PNC Financial Services Group Inc. bought a new position in SAB Biotherapeutics in the first quarter valued at approximately $29,000. Fifth Lane Capital LP bought a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $56,000. IFP Advisors Inc bought a new stake in shares of SAB Biotherapeutics during the 2nd quarter worth approximately $151,000. Bank of America Corp DE boosted its holdings in shares of SAB Biotherapeutics by 424.8% in the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock valued at $213,000 after buying an additional 45,084 shares during the last quarter. Finally, Kestra Advisory Services LLC grew its stake in shares of SAB Biotherapeutics by 434.6% in the first quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock valued at $236,000 after buying an additional 50,191 shares in the last quarter. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for infectious diseases, immune disorders and other serious health conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease.

SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle with human immune-system components to generate human antibodies.